A clinical trial testing the experimental pill daraxonrasib has drawn strong attention from researchers after results showed encouraging signs for people with advanced pancreatic cancer. Among 61 participants whose cancer had already spread to other organs, tumour growth stopped in 90% of patients. Just over 60% saw their tumours shrink or disappear, and scans showed no detectable cancer in about 8% roughly one in 12 people. At the one-year mark, 76.6% of patients were alive, compared with the usual 40 to 45% survival rate with chemotherapy alone.
Presented at a Barcelona cancer therapeutics symposium by Memorial Sloan Kettering oncologist Dr Wungki Park, the findings point to deeper tumour responses over an 18 month median follow up. Still, doctors stress that the pill is not a cure yet, and longer trials are needed to see how long the disease stays under control.
Pancreatic cancer remains notoriously hard to treat, with very low five-year survival rates once it spreads. Daraxonrasib works as a KRAS inhibitor, locking onto gene mutations that drive tumour growth in many pancreatic cancers and potentially other cancers as well. Cancer Research UK chief executive Michelle Mitchell called the results a major leap forward, while noting further studies are required before wider access or NHS assessment.